Interesting to read the response of clinicians regarding the...

Interesting to read the response of clinicians regarding the recent FDA review:-

https://endpts.com/clinicians-say-benefits-of-car-t-continue-to-outweigh-risk-of-t-cell-malignancies/

In it states the following:-

The agency has not responded to requests for comment on how many CAR-positive T-cell malignancies were detected and the severity of the cases. Bishop noted that CAR-positive cases do not necessarily mean the patient’s cancer was caused by CAR-T treatment, and more information will be necessary to determine whether patients were predisposed to T-cell lymphomas.

The fact that T-cell lymphomas is specifically mentioned, bodes extremely well for PTX-100.... the fact that it is a targeted therapy and not a Car-T therapy. Surely, the FDA will be more receptive to our upcoming submission.